EyePoint Pharmaceuticals Announces Conference Participation
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a biopharmaceutical company dedicated to advancing treatment options for serious retinal conditions, has exciting news. Jay S. Duker, M.D., President and CEO of EyePoint, will engage in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. This event is scheduled for a Thursday morning session and promises valuable insights into the company's innovative efforts.
Webcast Details for the Conference
Those interested in the presentation can access a live webcast through the Investors section of EyePoint's official website. The company also plans to provide an archived replay of the event, ensuring that stakeholders can revisit the insights shared during the chat. This replay will remain accessible for 90 days, allowing ample time for viewing.
Company Overview: EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical organization that focuses relentlessly on the development and commercialization of cutting-edge therapeutics aimed at enhancing the quality of life for patients suffering from serious retinal diseases. The company's lead product, DURAVYU™, is an innovative delivery system designed to treat VEGF-mediated retinal conditions by integrating vorolanib, a patented tyrosine kinase inhibitor, with advanced bioerodible technology.
Clinical Trials and Product Development
DURAVYU is currently undergoing assessment in two critical Phase 3 trials targeting wet age-related macular degeneration (wet AMD), with an expectation of topline data emerging in the near future. The product also successfully completed a Phase 2 clinical trial for diabetic macular edema (DME), fueling ongoing planning for future pivotal research.
Addressing Vision Loss in Patients
Despite the availability of current treatments, patients afflicted with wet AMD and DME continue to experience long-term vision loss. Wet AMD remains a leading cause of vision impairment among those aged 50 and older in the United States, which underscores the significance of EyePoint's mission to innovate and provide effective solutions.
Long-Term Vision and Community Commitment
EyePoint is committed not just to its products but also to its partnerships within the retinal community, emphasizing the creation of long-term value. Throughout its 30-year history, the company has successfully developed four approved drugs, significantly impacting tens of thousands of patients' lives.
Headquarters and Global Vision
The company is based in Watertown, Massachusetts, and operates a commercial manufacturing facility in Northbridge, Massachusetts. This strategic positioning allows EyePoint to maintain control over its production processes, crucial for delivering quality treatments worldwide.
Contact Information for Further Inquiries
For investor inquiries, Tanner Kaufman and Jenni Lu from FTI Consulting are available for direct communication. They can be reached at their respective phone numbers, providing a clear line for any discussions regarding EyePoint's ongoing projects and future direction. Additionally, media contact Amy Phillips from Green Room Communications is ready to assist with any press-related questions.
Frequently Asked Questions
What is the primary focus of EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals specializes in developing innovative therapies for patients with serious retinal diseases.
Who will represent EyePoint at the H.C. Wainwright conference?
Jay S. Duker, M.D., the President and CEO, will represent the company during the event.
How can I access the conference presentation?
The presentation can be accessed through the Investors section of EyePoint's website, with a replay available for 90 days afterward.
What is DURAVYU and its significance?
DURAVYU is an investigational treatment aimed at retinal diseases, designed to provide sustained delivery of vorolanib.
Where is EyePoint Pharmaceuticals headquartered?
EyePoint is headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge, Massachusetts.
